PreOmics Introduces a Novel BeatBox™ FFPE Workflow for Accelerated, In-depth Tissue Proteomics

At the AACR Annual Meeting 2023, PreOmics GmbH announced the launch of a BeatBox-based FFPE workflow, which simplifies, speeds up and standardizes FFPE sample preparation for deep, unbiased tissue proteomics by subsequent protein digestion and nanoLC-MS/MS analysis. The novel BeatBox workflow eliminates the need for xylene-based deparaffinization and enables fast and robust processing of up to 96 samples in parallel for discovery research, as well as for reproducible larger cohort translational and preclinical research and validation.

The BeatBox™ tissue homogenizer and cell lyser is a compact, affordable and stand-alone benchtop system for convenient, semi-automated sample homogenization of various tissue types and cells. With flexible input amounts from 1-50 mg, it consistently delivers reproducible results for LC-MS-based proteomics with scalable throughput from 1-96 samples. Already successful for fresh tissue and cell-line proteomics, with the novel FFPE protocol the BeatBox can now efficiently process FFPE samples for downstream tissue proteomics. Compared to sonication devices, the BeatBox requires no complex handling or additional water conditioning. FFPE or fresh frozen tissue homogenization takes just 10 minutes with push-button operation.

In a benchmark study, FFPE as well as fresh frozen mouse cardiac muscle, kidney, and liver tissue (provided by the Research Institute of Molecular Pathology in Vienna and the Histology Facility at Vienna BioCenter Core Facilities) was processed using the novel BeatBox FFPE workflow, as well as with a sonication approach. Peptides were analyzed on a timsTOF-HT mass spectrometer (Bruker Daltonics) in DIA-PASEF mode using a 30-minute nLC gradient. The BeatBox-based FFPE workflow was shown to increase the proteomic depth for FFPE, as well as for fresh frozen tissue on average by 14% to 43%, depending on tissue type. Typical Coefficients of Variation (CV) within replicates were below 10%, emphasizing the high repeatability of the homogenization process with the compact BeatBox instrument. Furthermore, the novel approach saves up to 4 hours of time in comparison to the sonication workflow, enabling parallelized high-throughput processing of 96 samples within one working day.

Dr. Michael Wierer, Director of the Proteomics Research Infrastructure at the University of Copenhagen, states: “We routinely analyze a large number of tissue samples at once, and to improve our efficiency, we have successfully adapted the BeatBox technology for tissue homogenization. Our latest discovery is that the BeatBox technology can efficiently homogenize paraffin-embedded tissue scrolls. This breakthrough now allows us to process large cohorts of FFPE tissue quickly, reproducibly, and with greater precision, opening up the possibility of large-scale biobank projects. By leveraging this technology, we are excited to uncover novel deep proteomics insights in the field of pathology research.”

Dr. Marcello Stein, Chief Marketing Officer of PreOmics, commented: “With our novel BeatBox-based FFPE workflow, researchers finally can simplify, speed-up and standardize FFPE sample preparation without the need of xylene-based deparaffinization to fully exploit its potential for unbiased, deep proteomics. We believe this is a leap forward for the preparation and subsequent proteomic analysis of large sample cohorts.”

Bruker Corporation (Nasdaq: BRKR) and PreOmics have a commercial agreement, enabling Bruker to offer the BeatBox-based tissue workflows for sale with Bruker’s timsTOF Pro mass spectrometer.

Have a look yourself: PreOmics representatives will be at the AACR Bruker booth #1818 to showcase the BeatBox and FFPE application note. The application note can be accessed at https://www.preomics.com/applications/ffpe.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version